15 articles for thisTarget
The following articles (labelled with PubMed ID or TBD) are for your review
PMID
Cmpds
Data
Article Title
Organization
36
Flat SAR of P3-methylsulphonamide based small molecule legumain inhibitors.

Queen'S University Belfast
30
P3 SAR exploration of biphenyl carbamate based Legumain inhibitors.

Queen'S University Belfast
42
Aza-peptidyl Michael acceptor and epoxide inhibitors--potent and selective inhibitors of Schistosoma mansoni and Ixodes ricinus legumains (asparaginyl endopeptidases).

Georgia Institute of Technology
17
Synthesis and evaluation of aza-peptidyl inhibitors of the lysosomal asparaginyl endopeptidase, legumain.

Stanford University School of Medicine
56
Discovery of Orally Available and Brain Penetrant AEP Inhibitors.

Roche Innovation Center Basel
6
Novel Haloacethydrazides as AEP Inhibitors for Treating Alzheimer's Disease.

Smith, Gambrell & Russell
6
3-Alkynyl Carboxamides as AEP Modulators for Treating Alzheimer's Disease.

Smith, Gambrell & Russell
10
Modular synthesis of 2,4-diaminoanilines as CNS drug-like non-covalent inhibitors of asparagine endopeptidase.

University of Florence
4
Aza-peptide Michael acceptors: a new class of inhibitors specific for caspases and other clan CD cysteine proteases.

School of Chemistry and Biochemistry and The Parker H. Petit Institute For Bioengineering and Bioscience
27
Identification and SAR exploration of a novel series of Legumain inhibitors.

Queen'S University Belfast
29
Development of a potent and selective cell penetrant Legumain inhibitor.

Queen'S University Belfast
4
Blockade of Asparagine Endopeptidase Inhibits Cancer Metastasis.

Emory Chemical Biology Discovery Center Emory University School of Medicine Atlanta
13
Heterocycle-substituted pyridyl benzothiophenes as kinase inhibitors

Allergan
4
Metalloenzyme inhibitor compounds

Viamet Pharmaceuticals
16
(3R)-4-[(3R)-3-Amino-4-(2,4,5-trifluorophenyl)butanoyl]-3-(2,2,2-trifluoroethyl)-1,4-diazepan-2-one, a selective dipeptidyl peptidase IV inhibitor for the treatment of type 2 diabetes.

Merck Research Laboratories